BioOutsourcing Europe 2026
Conference Details
Date: 24 June 2026
Time: To be announced
Duration: 2 days
Location: London, United Kingdom
Cost: £ 699 - £ 2895
Organiser: IMAPAC
Conference Description
About the Event
BioOutsourcing Europe 2026 is Europe’s leading senior-level forum dedicated entirely to the real-world performance of outsourced biomanufacturing for biologics and advanced therapies.
This is not a generic partnering event.
This is where operational leaders come to answer one question:
What actually drives reliable, high-performing, and inspection-ready outsourced manufacturing after the contract is signed?
We go deep into the operational, technical, digital, and compliance realities shaping CDMO delivery outcomes:
- Manufacturing performance, on-time delivery, and batch release;
- Speed, quality, and risk mitigation in technical transfer;
- Digital maturity, operational visibility, and data flow;
- CMC alignment and expectation-setting between pharma and CDMO;
- ESG, cybersecurity, supply resilience, and inspection preparedness.
If you’re responsible for ensuring your external manufacturing works – consistently, transparently, and at pace – this is the room.
Why Attend?
- Europe’s only event focused exclusively on outsourced biomanufacturing performance - not business development, not investment, not a partnering showcase;
- Purpose-built for MSAT, CMC, QA, Supply Chain, and Tech Ops leaders who live the realities of delivery, deviation, digital maturity, and scale-up;
- Practical case studies, closed-door benchmarking, and hands-on working sessions tailored to operational decision-makers;
- Direct access to CDMOs and innovators actively improving:
- Delivery metrics;
- Digital integration;
- Inspection readiness;
- Process scale-up;
- Tech transfer excellence.
This is where peers compare outcomes, challenge assumptions, and pressure-test what “good” looks like in outsourced manufacturing.
BioOutsourcing Europe 2026 will break down:
- How to improve reliability, delivery, and timeline predictability;
- What performance standards are emerging across biologics and ATMP programmes;
- How digitalisation, automation, and Industry 4.0 are redefining CDMO expectations;
- How supply chain resilience, cybersecurity, ESG, and regulatory pressure are reshaping sponsor–CDMO partnership models.
This is the state-of-the-industry forum for anyone responsible for what happens between PO and batch release.
Why London?
- One of Europe’s highest concentrations of biotechs outsourcing manufacturing;
- Near major CDMOs, investors, and global pharma operational hubs;
- Strong access to regulatory and policy networks;
- Excellent international connectivity for both European and US stakeholders.
London offers the ideal intersection of innovation, accessibility, and operational leadership - making it the natural home for this event.
© EuroJobsites 2026